Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
Incretin based therapies have been introduced into the treatment options of type 2 diabetes a few years ago. Among them, the orally active DPP-4 inhibitors have established themselves as insulinotropic agents. Their advantage is the glucose-dependent insulinotropic action without an intrinsic risk f...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411498/ |